Prognosis
Pfizer Says Covid Could Endure, Sees Long-Term Need for Shot
- Drugmaker sets two-phase business model for its virus vaccine
- Virus could find ways to come back again and again, CEO says
This article is for subscribers only.
Pfizer Inc. is preparing for the novel coronavirus to endure, leading to long-term demand for a seasonal shot to protect against Covid-19.
The New York pharmaceutical giant and its German partner BioNTech SE are front-runners in the race to develop a Covid-19 vaccine, employing a technology known as messenger RNA that can quickly advance through clinical studies. The companies dosed their first U.S. patient in a late-stage trial Monday, and they could be ready to seek approval from regulators as early as October.